share_log

中信证券:PD-L1 ADC药物有望触及全球超500亿美元IO市场

CITIC SEC: PD-L1 ADC drugs are expected to reach a global immuno-oncology market of over 50 billion dollars.

Breakings ·  Mar 22 01:14

CITIC SEC points out that PD-L1 ADC drugs combine the dual efficacy of immunotherapy and targeted ADCs, with a potential market scale expected to match the global market of over 50 billion dollars for immunotherapy drugs. The PD-L1 positivity rate for several high-incidence cancers in US markets exceeds 50%. Pfizer's PD-L1 ADC has demonstrated excellent efficacy in heavily treated populations with NSCLC and HNSCC, and its safety is controllable. Pfizer is expected to initiate two Phase III clinical trials in the second half of 2025, significantly increasing research certainty for the field. HENLIUS's PD-L1 ADC has also initiated five Phase II clinical trials in China around 2025, and it is expected to report Phase I clinical data in 2025. Therefore, attention should be paid to the clinical potential and commercial value of PD-L1 ADC.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 909

Recommended

Write a comment

Statement

This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.